JP2007510714A - 担体輸送スタチンの医薬製剤およびそれらの使用 - Google Patents

担体輸送スタチンの医薬製剤およびそれらの使用 Download PDF

Info

Publication number
JP2007510714A
JP2007510714A JP2006538993A JP2006538993A JP2007510714A JP 2007510714 A JP2007510714 A JP 2007510714A JP 2006538993 A JP2006538993 A JP 2006538993A JP 2006538993 A JP2006538993 A JP 2006538993A JP 2007510714 A JP2007510714 A JP 2007510714A
Authority
JP
Japan
Prior art keywords
statin
formulation
transporting
carrier
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510714A5 (enExample
Inventor
バトラー，ジャッキー
デヴェイン，ジョン
スターク，ポール
Original Assignee
アスファーマ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスファーマ・リミテッド filed Critical アスファーマ・リミテッド
Publication of JP2007510714A publication Critical patent/JP2007510714A/ja
Publication of JP2007510714A5 publication Critical patent/JP2007510714A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2006538993A 2003-11-04 2004-10-29 担体輸送スタチンの医薬製剤およびそれらの使用 Pending JP2007510714A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51677003P 2003-11-04 2003-11-04
US10/967,167 US8987322B2 (en) 2003-11-04 2004-10-19 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
PCT/IB2004/003849 WO2005041939A1 (en) 2003-11-04 2004-10-29 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof

Publications (2)

Publication Number Publication Date
JP2007510714A true JP2007510714A (ja) 2007-04-26
JP2007510714A5 JP2007510714A5 (enExample) 2007-11-29

Family

ID=34556205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538993A Pending JP2007510714A (ja) 2003-11-04 2004-10-29 担体輸送スタチンの医薬製剤およびそれらの使用

Country Status (9)

Country Link
US (2) US8987322B2 (enExample)
EP (2) EP1682095B1 (enExample)
JP (1) JP2007510714A (enExample)
AU (1) AU2004284884A1 (enExample)
CA (1) CA2543716C (enExample)
ES (2) ES2509869T3 (enExample)
IL (1) IL175134A0 (enExample)
NO (1) NO20062432L (enExample)
WO (1) WO2005041939A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
JP2011510974A (ja) * 2008-01-30 2011-04-07 ルピン・リミテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤の調節放出製剤
JP2016155811A (ja) * 2010-01-28 2016-09-01 メリオン・リサーチ・Ｉｉｉ・リミテッド 増強剤を含む固形医薬組成物およびその調製方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
AU2006329006B2 (en) * 2005-12-20 2013-02-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
MX2008011418A (es) * 2006-03-06 2008-09-22 Teva Pharma Composiciones de ezetimibe.
US7704977B2 (en) * 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
TR200800269A2 (tr) * 2008-01-15 2009-08-21 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Stabil farmasötik formülasyon ve hazırlama yöntemleri
TWI391150B (zh) * 2008-01-22 2013-04-01 Taiwan Biotech Co Ltd 腸溶性長效塗覆芯與藥物劑型及其製造方法
JP5671451B2 (ja) 2008-05-07 2015-02-18 メリオン・リサーチ・Ｉｉｉ・リミテッド ＧｎＲＨ関連化合物の組成物および調製プロセス
WO2010099255A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256191A (ja) * 1999-03-08 2000-09-19 Merck & Co Inc ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープン酸およびその塩

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4088884A (en) * 1976-01-26 1978-05-09 The United States Of America As Represented By The Secretary Of The Navy Wide aperture optical communications detector
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4557925A (en) 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
EP0465096A1 (en) 1990-06-26 1992-01-08 Merck & Co. Inc. Plasma cholesterol level lowering composition
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
AU2001253401B2 (en) * 2000-04-11 2006-12-07 Atherogenics, Inc Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US20020147232A1 (en) * 2000-05-26 2002-10-10 Claus Sundgreen Pharmaceutical compositions comprising desglymidodrine as an active drug substance
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
EP1465605A1 (en) 2002-01-11 2004-10-13 Athpharma Limited Pravastatin pharmaceutical formulations and methods of their use
MXPA05002074A (es) 2002-09-03 2005-06-08 Biovail Lab Int Srl Formulaciones farmaceuticas y metodos para la liberacion modificada de farmacos de estatina.
PL375712A1 (en) 2002-09-03 2005-12-12 Biovail Laboratories Inc. Pravastatin pharmaceutical formulations and methods of their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256191A (ja) * 1999-03-08 2000-09-19 Merck & Co Inc ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープン酸およびその塩
JP2002538202A (ja) * 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
JP2011510974A (ja) * 2008-01-30 2011-04-07 ルピン・リミテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤の調節放出製剤
JP2016155811A (ja) * 2010-01-28 2016-09-01 メリオン・リサーチ・Ｉｉｉ・リミテッド 増強剤を含む固形医薬組成物およびその調製方法

Also Published As

Publication number Publication date
CA2543716C (en) 2016-05-31
US20050119331A1 (en) 2005-06-02
ES2500924T3 (es) 2014-10-01
EP1682095B1 (en) 2014-07-02
WO2005041939A1 (en) 2005-05-12
EP2319501A1 (en) 2011-05-11
IL175134A0 (en) 2006-09-05
CA2543716A1 (en) 2005-05-12
NO20062432L (no) 2006-08-04
US20150164893A1 (en) 2015-06-18
US8987322B2 (en) 2015-03-24
AU2004284884A1 (en) 2005-05-12
EP2319501B1 (en) 2014-06-18
ES2509869T3 (es) 2014-10-20
EP1682095A1 (en) 2006-07-26

Similar Documents

Publication Publication Date Title
US20150164893A1 (en) Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
US20080260818A1 (en) Controlled Absorption of Statins in the Intestine
US20100055173A1 (en) Release of statins in the intestine
JP2006503023A (ja) スタチン薬物の放出調節ための医薬品製剤および方法
US6967218B2 (en) Pravastatin pharmaceutical formulations and methods of their use
US20090196889A1 (en) Controlled absorption of statins in the intestine
EP2033631A2 (en) Pravastatin pharmaceutical formulations and methods of their use
MXPA06004777A (es) Formulaciones farmaceuticas para estatinas de transporte mediadas por portadores y usos de las mismas
EP1905431A1 (en) Pravastatin pharmaceutical formulations and methods of their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071009

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110719